Erectile dysfunction (ED) is a common male disorder that directly affects the quality of life of patients and their spouses. The Massachusetts Men’s Age-Related Health Study (MMAS) reported that the prevalence of ED among men aged 40-70 years in Boston, USA was 52%, and the prevalence of mild, moderate and severe ED was 17.2%, 25.2% and 9.6%, respectively. The incidence of ED at follow-up was 25.9 cases/1000 people/1 year. With the accelerated aging of the population, the number of ED patients is increasing year by year. It is expected that by 2025, 322 million men worldwide will be affected by ED. Although people have been pursuing the same goal: curing the disease. However, according to current research advances, the available treatments can only: improve the symptoms of ED (improve the disease). The current ED treatment is divided into three lines of treatment. First-line therapy (First-line therapy) 1, psychotherapy 2, oral medication 1) selective PDE5 inhibitors (sildenafil, vardenafil and tadalafil) 2) androgen supplementation 3, vacuum negative pressure assisted erection (VCD) Second-line therapy (Second-line therapy) 1, transurethral drug delivery 2, local penile cavernosal The commonly used drugs are Papaverine (PDE inhibitor) and Phentolamine (a blocker) Third-line therapy 1) Vascular surgery 1) Penile arterial revascularization 2) Penile venous vascular blocking 2) Penile prosthesis implantation 4. Stem cell therapy 2) Extracorporeal counterpulsation therapy 3) Low energy extracorporeal shock wave therapy